Results speak for themselves. The ph2 her-vaxx completion saw no deal off the back of results, they're clearly not good enough to warrant a financial engagement by BP.
IMU is now (slowly) conducting ph2 combo trials at shareholder expense to try and salvage a drug that wasn't appealing on its own merits. As I said in a previous post, the cost/benefit of continuing these ph2 combo trials needs to be at the forefront of shareholder concerns before another 50m that could be better spent elsewhere gets chewed up.
The above aside, it looks like confirmation of a deal or TO happening any time in the next 2+ years is dead.
Ann: Imugene Corporate Presentation, page-62
-
- There are more pages in this discussion • 185 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.9¢ |
Change
0.005(9.26%) |
Mkt cap ! $433.6M | |||
| Open | High | Low | Value | Volume |
| 5.5¢ | 5.9¢ | 5.4¢ | $1.489M | 25.99M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 35252 | 5.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 6.0¢ | 1753430 | 24 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| IMU (ASX) Chart |